-+ 0.00%
-+ 0.00%
-+ 0.00%

Boundless Bio to merge with Serapha Bio in all-stock deal, shares to trade as AATD

PUBT·06/23/2026 11:30:37
Listen to the news
Boundless Bio to merge with Serapha Bio in all-stock deal, shares to trade as AATD
  • Boundless Bio to combine with privately held Serapha Bio in an all-stock merger; the combined company will operate as Serapha Bio.
  • Serapha secured about USD 230 million in concurrent private placements; USD 138 million funded, with USD 92 million set to close near closing.
  • At closing, Serapha holders are expected to own about 96.3% of the combined company; pre-merger Boundless holders about 3.7%.
  • Boundless plans a pre-close cash dividend to its stockholders of about USD 44 million to USD 48 million, subject to closing adjustments.
  • Closing is targeted for the fourth quarter of 2026; shares are expected to trade on Nasdaq under the ticker AATD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230730PRIMZONEFULLFEED9750796) on June 23, 2026, and is solely responsible for the information contained therein.